Omeza Combination Therapy for the Management and Treatment of Chronic Cutaneous Wounds/Ulcers of Multiple Etiologies

A Clinical Study to Evaluate the Omeza Combination Therapy for the Management and Treatment of Chronic Cutaneous Wounds/Ulcers of Multiple Etiologies

The goal of this clinical trial is to evaluate the use of Omeza combination therapy with Standard of Care. The main question it aims to answer is:

- Can Omeza combination therapy with Standard of Care enable chronic wounds to begin a healing trajectory in a 4-week period?

Patients will be treated with:

• Omeza combination therapy
• Standard of Care

Study Overview

• Status: Recruiting
• Conditions: Non-healing Wound; Non-Healing Ulcer of Skin
• Intervention / Treatment: Combination product: Omeza Products Used in Combination

Detailed Description

The goal of this clinical trial is to demonstrate that the Omeza combination therapy with Standard of Care can enable chronic wounds to move from chronicity to a healing trajectory in a 4-week period. The trial is targeting those wounds that have failed therapy for approximately 3 months prior to trial enrollment and are chronic by definition of no change in area size after 2 weeks of optimal treatment. The inclusion and exclusion criteria applied to chronic wound clinical trials is being broadened with the intention to include outliers, reduce bias, and to evaluate results in a real-world scenario.

• Study Type: Interventional
• Enrollment (Estimated): 100
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Kevin Keller, BSc; Phone Number: 1-910-789-9457; Email: kkeller@catawbaresearch.com
• Study Contact Backup: Name: Suzanne Bakewell, Ph.D.; Phone Number: 1-813-765-5596; Email: sbakewell@omeza.com

Study Locations

• United States
  • New Mexico
    • Santa Fe, New Mexico, United States, 87505
      • Recruiting
      • CHRISTUS St. Vincent
      • Contact: Tamara Flys, Ph.D.; Phone Number: 505-913-3027; Email: Tamara.Flys@stvin.org
      • Principal Investigator: Gerit Mulder, DPM

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Subject is at least 18 years old and female subjects are not pregnant
• Willing and able to comply with Trial procedures, including Trial visits and Trial dressing regimens
• Targeted chronic wound/ulcer has been chronically present for at least two (2) months (8 weeks) as of the date the subject signs consent for study
• Study target chronic wound/ulcer size is a minimum of 2.0 cm2 and a maximum of 100.0 cm2 without exposed tendon, muscle or bone
• Willing and able to comply with study procedures, including study visits and study dressing regimens including ability of the subject to tolerate limb compression bandage, when applicable
• Subject has read and signed the IRB-approved Informed Consent Form before screening procedures are undertaken.

Additional Inclusion Criteria (for Subjects with Wounds/Ulcers in Lower Extremities):

• The affected limb must have adequate perfusion confirmed by vascular assessment. Any one of the following methods performed within 1 or 2 months of the first screening visit are acceptable:

  1. Ankle Brachial Index (ABI) between 0.8 and 1.3
  2. Toe Brachial Index (TBI) > 0.6
  3. Transcutaneous oximetry (TCOM) >40mmHg
  4. Pulse volume recording (PVR): biphasic or triphasic waveforms
• Confirmation of venous disease by non-invasive venous studies with either Doppler confirmed venous reflux or having ≥ 2 clinical characteristics of venous insufficiency (varicose veins, lipodermatosclerosis, venous dermatitis, atrophie blanche, edema). Biopsy done to exclude other skin conditions e.g., cancer on ulcers ≥ 6 months
• Have a venous ulcer between the knee and ankle, at or above the malleolus
• Subject understands and is willing to participate in the clinical study visits including compression if needed for minimum 14 days (compression dressing changed once weekly) prior to study start, participate in the informed consent process, and can comply with weekly visits and the follow-up regimen
• If more than one chronic wound/ulcer is present on the same leg, they must be greater than 2 cm apart and only the larger chronic wound/ulcer will be included in the study (i.e., targeted lesion)

Additional Inclusion Criteria (for Subjects with Diabetic Foot Ulcer):

• Diagnosed as having Type 1 or Type 2 diabetes
• Any lower extremity wound should have at least one method of arterial testing (ABI, TBI, Arterial Doppler with Waveforms, Pulse Volume Recordings, Skin Perfusion Pressure, TcPO2) within 1 or 2 months of the first screening visit.
• Presence of a DFU, Wagner 1 or 2 (see Appendix D for definitions), extending at least through the dermis provided it is below the level of the medial or lateral malleolus.
• Known HbA1c of ≤12% within 6 months
• The target wound will be located on the foot or ankle and will be the largest ulcer if two or more DFUs are present with the same Wagner grade and will be the only one evaluated in the study. If other ulcerations are present on the same foot, they must be more than 1 cm distant from the target wound

Exclusion Criteria:

• Targeted chronic wounds/ulcers exhibit clinical signs and symptoms of infection, as evidenced by tissue necrosis, redness, pain, and/or purulent drainage and/or receiving systemic antibiotics for the treatment of such*

• Targeted chronic wound/ulcer treated with a topical antibiotic within the last 7 days prior to first treatment with Omeza products.

  a. NOTE: washout of topical antibiotics and antibacterial treatments (eg. Silver, manuka honey, iodine, etc) is at least 7 days before first treatment with Omeza products.

• Targeted chronic wound/ulcer has been treated with any placental derived products, engineered material (e.g., Apligraf® or Dermagraft®) or other scaffold materials (e.g., Oasis, PuraPly AM or Matristem) within the last 30 days.
• Targeted chronic wound/ulcer requires enzymatic debridement during the study
• Targeted chronic wound/ulcer decreases in area by 30% or more during the 14 days screening/run-in period.
• Subjects who are unable to understand the aims and objectives of the trial or have a known history of poor adherence with medical treatment.
• Subject is medically unable to consent (due to head trauma, coma, etc.) or cognitively impaired (due to being mentally challenged, having Alzheimer's, etc.)
• Presence of any condition(s) that seriously compromises the subject's ability to complete this study.
• Subjects with a BMI>65
• Subject has any history of fish allergy or a known sensitivity to any of the SoC materials which contact the skin
• Presence of any monophasic waveforms on segmental Arterial Doppler/Pulse Volume Recording
• Subject is on dialysis
• Any active cancer other than a nonmelanoma skin cancer; any previous cancer must be in remission for at least 1 year: bone cancer of metastatic disease of the affected limb, or has had chemotherapy within the last 12 months
• Suspicion of malignancy within chronic wounds/ulcers: A biopsy must be performed for any wound that has been present for > 6 months and has not previously been biopsied. A biopsy should be performed regardless of duration of wound If a clinical suspicion of malignancy exists in the opinion of the Investigator.
• Life expectancy < 6 months
• Subject has received within 28 days of screening a treatment which is known to interfere with or affect the rate and quality of wound healing (e.g., thrombolysis, systemic steroids, immunosuppressive therapy, autoimmune disease therapy, dialysis, radiation therapy at wound site, chemotherapy) or who may receive such medications during the screening period or who has anticipated to require such medications during the course of the study at the discretion of the treatment PI.
• Untreated osteomyelitis
• Acute deep venous thrombosis
• Allergy to lidocaine and/or epinephrine
• Subject's inability to successfully tolerate compression therapy that is changed weekly
• All females of childbearing potential who are not using a highly effective method of birth control (failure rate less than 1% per year), such as implants, injectables, combined oral contraceptives, some IUDs, practice sexual abstinence or have a vasectomized partner.

• The use of the following treatments are prohibited within 30 days prior to randomized treatment and throughout the study:

  1. Heat lamps
  2. UV lights
  3. Whirlpool baths
  4. Hyperbaric oxygen
  5. Topical or local insulin administration

Additional Exclusion Criteria (for Subjects with Wounds/Ulcers in Lower Extremities):

• The affected limb must have adequate perfusion confirmed by vascular assessment. Any of the following methods performed within 1 or 2 months of the first screening visit are exclusionary:

  1. Ankle Brachial Index (ABI) less than 0.7 or greater than 1.3
  2. Toe Brachial Index (TBI) < 0.6
  3. Transcutaneous oximetry (TCOM) <40mmHg
• Suspicion of malignancy within VLU
• Acute deep venous thrombosis
• Study target chronic wound/ulcer extends more than 50% below the malleolus.

Additional Exclusion Criteria (for Subjects with Diabetic Foot Ulcer):

• Target wound deemed by the investigator to be caused by a medical condition other than diabetes or subject has wounds secondary to a disease other than diabetes (e.g. vasculitis, neoplasms, or hematological disorders)

• The affected limb of the diabetic subject must have adequate perfusion confirmed by vascular assessment. Any of the following methods performed within 1 or 2 months of the first screening visit are exclusionary:

  1. Ankle Brachial Index (ABI) between 0.8 and <1.3
  2. Toe Brachial Index (TBI > 0.6
• The subject is unable to safely ambulate with the use of a study required offloading method
• Subject has unstable Charcot foot or Charcot with bone exposed that could inhibit wound healing
• Osteomyelitis or bone infection of the affected foot as verified by x-ray within 30 days prior to randomization. (In the event of an ambiguous diagnosis, the subject will not be enrolled)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Omeza Products Used in Combination; Subjects in this single-arm study will have the targeted wound/ulcer treated with Omeza combination therapy which includes the use of lidocaine lavage (2mL vial), cod liver oil skin protectant (2mL vial), and collagen matrix wound dressing (2ml vial). Patients will be treated weekly for four weeks. Treatment may be continued weekly for an additional 8 weeks with participant and investigator agreement.

Combination product: Omeza Products Used in Combination; Subjects in this single-arm study will have the targeted wound/ulcer treated with Omeza combination therapy which includes the use of the following products: Omeza Lidocaine Lavage; Omeza Collagen Matrix; Omeza Skin Protectant At each treatment (on days 0, 7, 14, 21, and 28; +/- 3 days each), the patient's wound/ulcer will be cleaned with Omeza Lidocaine Lavage. Omeza Collagen Matrix will be applied as the primary dressing and Omeza Skin Protectant will be applied on periwound and surrounding intact skin. Treatments may be repeated during an optional 8 additional weeks (on days 35, 42, 49, 56, 63, 70, and 77; +/- 3 days each).; Other Names: Omeza Lidocaine Lavage (drug), Omeza Collagen Matrix (device), and Omeza Skin Protectant (drug)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Chronicity of Wound Healing	The proportion of subjects with a clinically significant improvement in Study Ulcer Exudate Assessments at 4 weeks compared to baseline assessment.	4 weeks
Change in Wound Area	Percent change in wound area at 4 weeks as measured by wound imaging software. Sub-characterization will include wounds with baseline area of greater than or less than 100㎟.	4 weeks
Wound Healing	The objective response rate (ORR) will be used to define effectiveness at 4 weeks. The ORR is defined as the proportion of subjects at 4 weeks that have had at least a 40% reduction in the area of the wound volume from Day 0 measurements measured by wound imaging software.	4 weeks
Wound Closure	Proportion of subjects that have had complete closure at or prior to 12 weeks of treatment.	12 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Improvement in Quality of Life	Change in the subject's Quality of Life (QoL). A numerical validated QoL scale (wound QoL Appendix F) specific for wound healing will be provided for participants to complete on a scheduled visit basis up to 12 weeks from Day 0.	12 weeks
Reported Pain Perception	Reported changes in pain perception will use a 10 cm Visual Analogue Scale and subjects will mark on the line from no pain to worst pain possible each scheduled visit.	12 weeks
Drainage/Exudate and Infection	Change in drainage/exudate and infection assessments. Drainage/exudate and infection assessment will be provided by the investigator in assessment of wounds at each week when changing dressings at each visit.	12 weeks
Enhanced Activities in Daily Living	Changes in the enhanced activities in daily living. Enhanced activities in daily living will be measured in an instrumental ADL scale at scheduled visits: the Barthel Index that measures the following criteria: chair/bed transfers, ambulation, ambulation/wheelchair, stair climbing, toilet transfers, bowel control, bladder control, bathing, dressing, personal hygiene, and feeding.	12 weeks
Time to Closure	This will be the time from Day 0 to the day that 100% or reepithelization without drainage or exudate has occurred. In addition, any wounds/ulcers that have not had complete closure by week 12 the maximum reported closure will be reported, and the data censored at 12 weeks.	12 weeks
Incidence of Healing	The proportion of subjects in which complete closure has occurred by Week 12.	12 weeks

Collaborators and Investigators

• Sponsor: Omeza, LLC
• Investigators: Study Director: Desmond Bell, DPM, Omeza Holdings, Inc

Study record dates

Study Major Dates

• Study Start (Actual): July 11, 2022
• Primary Completion (Estimated): April 1, 2024
• Study Completion (Estimated): August 1, 2024

Study Registration Dates

• First Submitted: June 19, 2023
• First Submitted That Met QC Criteria: June 19, 2023
• First Posted (Actual): June 27, 2023

Study Record Updates

• Last Update Posted (Actual): June 27, 2023
• Last Update Submitted That Met QC Criteria: June 19, 2023
• Last Verified: June 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Ulcer; Wounds and Injuries; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Arrhythmia Agents; Central Nervous System Depressants; Peripheral Nervous System Agents; Sensory System Agents; Anesthetics; Membrane Transport Modulators; Anesthetics, Local; Voltage-Gated Sodium Channel Blockers; Sodium Channel Blockers; Lidocaine
• Other Study ID Numbers: OM-CTP-002

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: No